Your browser is no longer supported. Please, upgrade your browser.
ARQL ArQule, Inc. daily Stock Chart
ARQL [NASD]
ArQule, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own0.80% Shs Outstand120.28M Perf Week107.60%
Market Cap2.41B Forward P/E- EPS next Y-0.38 Insider Trans47.87% Shs Float118.69M Perf Month158.57%
Income-38.60M PEG- EPS next Q-0.10 Inst Own95.60% Short Float16.07% Perf Quarter158.24%
Sales4.80M P/S502.80 EPS this Y60.00% Inst Trans3.53% Short Ratio4.96 Perf Half Y109.45%
Book/sh1.27 P/B15.80 EPS next Y-5.60% ROA-27.00% Target Price17.00 Perf Year493.64%
Cash/sh1.04 P/C19.28 EPS next 5Y8.00% ROE-33.20% 52W Range2.23 - 20.45 Perf YTD624.37%
Dividend- P/FCF- EPS past 5Y16.90% ROI-14.60% 52W High-1.88% Beta2.21
Dividend %- Quick Ratio8.30 Sales past 5Y10.10% Gross Margin- 52W Low799.78% ATR1.04
Employees36 Current Ratio8.30 Sales Q/Q-96.00% Oper. Margin- RSI (14)87.70 Volatility1.53% 5.01%
OptionableYes Debt/Eq0.10 EPS Q/Q-70.60% Profit Margin- Rel Volume1.38 Prev Close19.99
ShortableYes LT Debt/Eq0.06 EarningsJan 29 BMO Payout- Avg Volume3.85M Price20.07
Recom2.50 SMA2081.52% SMA50106.33% SMA200144.90% Volume5,313,330 Change0.38%
Dec-10-19Downgrade ROTH Capital Buy → Neutral
Dec-10-19Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-10-19Downgrade H.C. Wainwright Buy → Neutral
Dec-10-19Downgrade Cantor Fitzgerald Overweight → Neutral
Nov-27-19Resumed B. Riley FBR Buy $14
Nov-05-19Initiated Wolfe Research Outperform
Oct-17-19Resumed Cantor Fitzgerald Overweight $16
Oct-17-19Initiated Cantor Fitzgerald Overweight $16
Sep-16-19Initiated H.C. Wainwright Buy $13
Apr-11-19Initiated RBC Capital Mkts Outperform $9
Jun-18-18Reiterated Needham Buy $6 → $7
May-08-18Reiterated Needham Buy $5 → $6
Apr-05-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-22-18Initiated ROTH Capital Buy $5
Feb-02-18Initiated B. Riley FBR, Inc. Buy $3
Dec-14-17Upgrade Needham Hold → Buy $5
Dec-21-15Upgrade RBC Capital Mkts Sector Perform → Outperform $4 → $5
Dec-09-15Resumed Leerink Partners Mkt Perform
May-12-14Reiterated MLV & Co Hold $3 → $1.75
May-24-13Reiterated MLV & Co Hold $2.25 → $3
Dec-12-19 03:49PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates ArQule, Inc. PR Newswire
01:19PM  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Mergers GlobeNewswire
07:34AM  Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting MarketWatch
Dec-11-19 04:16PM  Why Merck, Sanofi News Helped This Biotech Rocket 32% Over Three Days Investor's Business Daily
03:15PM  URGENT NEWS: Monteverde & Associates PC Continues its Legal Inquiry for the Recent Buyout ACCESSWIRE
07:21AM  The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint Benzinga
Dec-10-19 06:53PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of ArQule, Inc. - (NasdaqGS: ARQL) ACCESSWIRE
04:16PM  Why Biotech ETFs are Surging to New Highs Zacks
11:57AM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of ArQule, Inc - ARQL PR Newswire
10:10AM  Biotech ETFs Hit New Highs on Deal Activities Zacks
09:42AM  Merck to Buy ArQule for $2.7B to Boost Cancer Portfolio Zacks
09:07AM  Company News for Dec 10, 2019 Zacks
08:27AM  Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms Zacks
07:56AM  The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares Benzinga
07:14AM  Drug manufacturers have spent a record $342 billion on M&A in 2019 MarketWatch
Dec-09-19 04:45PM  U.S. stock market snaps 3-day win streak as China tariff deadline comes in focus MarketWatch +103.88%
04:23PM  Why This $2.7 Billion Merck Takeover Could Pressure J&J, Eli Lilly Investor's Business Daily
04:18PM  US STOCKS-Wall St falls as Apple, health shares drag, tariff deadline looms Reuters
02:43PM  US STOCKS-Wall St falls as health, tech shares drag, tariff deadline looms Reuters
01:19PM  US STOCKS-Wall Street drops as tariff deadline looms Reuters
01:15PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of ArQule, Inc. to Merck & Co., Inc. is Fair to Shareholders ACCESSWIRE
01:08PM  PreMarket Prep Recap: Small Biotech Firms Looking Healthy, Street Fades Macy's Downgrade Benzinga
01:04PM  ARQULE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ARQL and Encourages Investors to Contact the Firm PR Newswire
12:10PM  ARQULE, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout ACCESSWIRE
12:03PM  Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 9, 2019: MRK, PCG, M, DPLO, CHWY Benzinga
12:00PM  Why This $2.7 Billion Merck Takeover Could Pressure J&J, Eli Lilly Investor's Business Daily
11:59AM  ArQule Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of ArQule, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm ARQL GlobeNewswire
11:51AM  Merck to buy Massachusetts cancer drug developer for $2.7 billion American City Business Journals
11:38AM  US STOCKS-Wall Street treads water with tariff deadline in focus Reuters
11:04AM  Heres the hard-money call for why the boom in the economy and stock market will continue MarketWatch
10:48AM  US STOCKS-S&P 500, Nasdaq edge higher; tariff deadline in focus Reuters
10:44AM  Drug Giants Pay Hefty Premiums as Cancer-Drug Race Heats Up Bloomberg
10:16AM  Week Begins with Biotech Mergers Zacks
10:06AM  Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More Zacks
09:59AM  Merck drops $2.7B on 26-year-old Burlington biotech American City Business Journals
09:42AM  Merck and Sanofi Are Both Acquiring Cancer-Drug Developers Barrons.com
08:57AM  US STOCKS-Wall St set to drop after weak Chinese data; Tariff deadline looms Reuters
08:05AM  ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting Business Wire
07:37AM  (ARQL) Alert: Johnson Fistel Investigates Proposed Sale of ArQule, Inc.; Is $20 a Fair Price? PR Newswire
07:11AM  UPDATE 2-Merck pushes deeper into targeted cancer therapy with $2.7 bln ArQule deal Reuters
06:56AM  Merck to acquire ArQule for $20 per share in cash or about $2.7 billion MarketWatch
06:50AM  Merck to buy cancer drug developer ArQule for $2.7 bln in cash Reuters
06:45AM  Merck to Acquire ArQule, Advancing Leadership in Oncology Business Wire
04:47AM  Merck & Co. Acquires Cancer Drug Specialist ArQule For $2.7 Billion TheStreet.com
03:45AM  Stocks - Canopy Growth, ArQule Rise in Premarket; Microsoft Edges Lower Investing.com
Dec-07-19 08:09AM  Hedge Funds Are Starting To Cash Out Of ArQule, Inc. (ARQL) Insider Monkey
Dec-02-19 08:57AM  Shareholders Are Raving About How The ArQule (NASDAQ:ARQL) Share Price Increased 623% Simply Wall St.
Nov-25-19 07:00AM  ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting Business Wire +9.71%
Nov-15-19 02:13PM  Edited Transcript of ARQL earnings conference call or presentation 30-Oct-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-13-19 07:00AM  ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019 Business Wire
Nov-06-19 09:05AM  ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies Business Wire -17.88%
Oct-30-19 08:25AM  ArQule (ARQL) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:00AM  ArQule Reports Third Quarter 2019 Financial Results Business Wire
Oct-29-19 04:01PM  ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Business Wire
Oct-28-19 05:15PM  Hedge Funds Have Never Been This Bullish On ArQule, Inc. (ARQL) Insider Monkey
Oct-21-19 07:00AM  ArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformations at 2019 ASHG Annual Meeting Business Wire
Oct-16-19 07:00AM  ArQule to Report Third Quarter 2019 Financial Results on October 30, 2019 Business Wire
07:00AM  ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Business Wire
Oct-15-19 09:00AM  All You Need to Know About ArQule (ARQL) Rating Upgrade to Buy Zacks
Oct-08-19 08:47AM  Health Check: How Prudently Does ArQule (NASDAQ:ARQL) Use Debt? Simply Wall St.
07:00AM  ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting Business Wire
Oct-03-19 10:56AM  ArQule (ARQL) in Focus: Stock Moves 6.2% Higher Zacks +8.88%
Oct-02-19 07:00AM  ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum Business Wire +6.24%
Sep-26-19 07:00AM  ArQule to Present at the 2019 Cantor Global Healthcare Conference on October 3, 2019 Business Wire
Sep-17-19 07:00AM  ArQule to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on September 24, 2019 Business Wire
Aug-30-19 02:39PM  ArQule: Buy the Dip? Motley Fool
02:20AM  Edited Transcript of ARQL earnings conference call or presentation 7-Aug-19 1:00pm GMT Thomson Reuters StreetEvents
Aug-28-19 07:00AM  ArQule to Participate in Citis 14th Annual Biotech Conference on September 4, 2019 Business Wire +5.11%
Aug-09-19 11:07AM  What Kind Of Shareholders Own ArQule, Inc. (NASDAQ:ARQL)? Simply Wall St.
Aug-07-19 11:23PM  Arqule Inc (ARQL) Q2 2019 Earnings Call Transcript Motley Fool -8.38%
08:45AM  ArQule (ARQL) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:00AM  ArQule Reports Second Quarter 2019 Financial Results Business Wire
Aug-06-19 02:18PM  Arqule's Earnings Preview Benzinga
12:00PM  ArQule (ARQL) to Post Q2 Earnings: What's in the Cards? Zacks
Aug-05-19 07:00AM  ArQule to Participate in the BTIG Biotechnology Conference on Monday, August 12, 2019 Business Wire
Jul-31-19 10:36AM  Analysts Estimate ArQule (ARQL) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-24-19 09:00AM  What Makes ArQule (ARQL) a New Buy Stock Zacks
07:00AM  ArQule to Report Second Quarter 2019 Financial Results on August 7, 2019 Business Wire
Jul-12-19 07:15AM  5 Best Biotech Stocks of 2019 So Far Motley Fool
Jul-08-19 01:58PM  Here's Why ArQule Jumped 53.1% in June Motley Fool
Jun-27-19 01:09PM  ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Business Wire
Jun-26-19 08:54AM  Do Options Traders Know Something About ArQule (ARQL) Stock We Don't? Zacks
Jun-25-19 03:16PM  Here's the Surprising Reason ArQule Shares Rose as Much as 11% Today Motley Fool +8.09%
07:15AM  The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership Benzinga
07:00AM  ArQule Announces Pricing of $90 Million Public Offering of Common Stock Business Wire
Jun-24-19 04:37PM  ArQule Announces Commencement of Proposed Public Offering of Common Stock Business Wire
01:27PM  Did Hedge Funds Drop The Ball On ArQule, Inc. (ARQL) ? Insider Monkey
Jun-18-19 04:01PM  ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019 Business Wire
07:31AM  The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale Benzinga
Jun-17-19 03:22PM  Biotech ETFs Are Breaking Out on Pfizers Array Biopharma Deal ETF Trends +16.83%
03:21PM  ArQule Hits 12-Year High Following Favorable Midstage Study Results Benzinga
01:10PM  2 Rallying Pharma Stocks Roping In Option Bulls Schaeffer's Investment Research
12:37PM  Here's Why ArQule Is Soaring Again Today Motley Fool
09:31AM  Company News For Jun 17, 2019 Zacks
09:00AM  ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an Oral Presentation at the European Society of Human Genetics Conference Business Wire
Jun-15-19 12:38PM  The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs Benzinga
Jun-14-19 01:18PM  ArQule News: ARQL Stock Skyrockets on Blood Cancer Study Results InvestorPlace +30.37%
12:56PM  A Look At Benzinga Pro's Most-Searched Tickers For June 14 Benzinga
11:52AM  Here's Why ArQule Shares Rose as Much as 44.7% Today Motley Fool
10:31AM  ArQule Jumps on Positive Phase 1 Blood Cancer Trial Results TheStreet.com
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ZENNER PATRICK JDirectorSep 24Option Exercise6.1425,000153,500122,216Sep 25 10:40 AM
Lawrence Peter SPresident and COOSep 16Option Exercise3.4214,62050,00092,363Sep 17 02:03 PM
Pucci PaoloChief Executive OfficerSep 11Option Exercise7.955,00039,750707,417Sep 12 10:46 AM
SCHAMBER BLAINEVP Finance, CAOAug 15Option Exercise2.568,55021,89655,267Aug 19 01:54 PM
Nussbaum RanDirectorJun 27Buy9.75307,6922,999,9973,482,224Jul 01 11:50 AM
SCHEGERIN MARCChief Financial OfficerJun 06Option Exercise2.5210,00025,20013,039Jun 10 01:33 PM
LINDSAY RONALD MDirectorApr 15Option Exercise3.8710,00038,70060,800Apr 16 12:28 PM
LOBERG MICHAEL DDirectorApr 10Option Exercise3.8710,00038,700172,514Apr 11 12:12 PM
Messenger William GDirectorApr 09Option Exercise3.8710,00038,70020,000Apr 11 12:22 PM
ZENNER PATRICK JDirectorApr 05Option Exercise3.8715,00058,05097,216Apr 08 04:58 PM
BARABE TIMOTHY CDirectorApr 04Option Exercise3.8710,00038,700146,897Apr 08 04:17 PM
Pucci PaoloChief Executive OfficerMar 15Option Exercise1.1650,00058,000618,208Mar 18 03:41 PM